| abstract |
The invention includes (1) anhydrous crystalline forms of N- [1- (2-ethoxyethyl) -5- (N-ethyl-N-methylamino) -7- (4-methylpyridin-2-ylamino) -1H-pyrazolo [4,3 -d] pyrimidine-3-carbonyl] methanesulfonamide, (2) pharmaceutical compositions containing at least one such form, (3) methods for treating a phosphodiesterase-5 mediated condition using at least one such form, and (4) methods for producing such forms. Compound, N- [1- (2-ethoxyethyl) -5- (N-ethyl-N-methylamino) -7- (4-methylpyridin-2-ylamino) -1H-pyrazolo [4,3-d] pyrimidin-3 -carbonyl] methanesulfonamide, has the following structure 1: |